Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry.
Wayangankar SA, Bangalore S, McCoy LA, Jneid H, Latif F, Karrowni W, Charitakis K, Feldman DN, Dakik HA, Mauri L, Peterson ED, Messenger J, Roe M, Mukherjee D, Klein A. Wayangankar SA, et al. Among authors: mauri l. JACC Cardiovasc Interv. 2016 Feb 22;9(4):341-351. doi: 10.1016/j.jcin.2015.10.039. Epub 2016 Jan 20. JACC Cardiovasc Interv. 2016. PMID: 26803418 Free article.
Temporal Trends in the Risk Profile of Patients Undergoing Outpatient Percutaneous Coronary Intervention: A Report from the National Cardiovascular Data Registry's CathPCI Registry.
Vora AN, Dai D, Gurm H, Amin AP, Messenger JC, Mahmud E, Mauri L, Wang TY, Roe MT, Curtis J, Patel MR, Dauerman HL, Peterson ED, Rao SV. Vora AN, et al. Among authors: mauri l. Circ Cardiovasc Interv. 2016 Mar;9(3):e003070. doi: 10.1161/CIRCINTERVENTIONS.115.003070. Circ Cardiovasc Interv. 2016. PMID: 26957417
Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Shah RM, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, Yeh RW. Secemsky EA, et al. Among authors: mauri l. JACC Cardiovasc Interv. 2016 Dec 12;9(23):2376-2386. doi: 10.1016/j.jcin.2016.09.020. Epub 2016 Nov 9. JACC Cardiovasc Interv. 2016. PMID: 27838271 Free article.
Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention.
Federspiel JJ, Anstrom KJ, Xian Y, McCoy LA, Effron MB, Faries DE, Zettler M, Mauri L, Yeh RW, Peterson ED, Wang TY; Treatment With Adenosine Diphosphate Receptor Inhibitors–Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Investigators. Federspiel JJ, et al. Among authors: mauri l. JAMA Cardiol. 2016 Sep 1;1(6):655-65. doi: 10.1001/jamacardio.2016.1783. JAMA Cardiol. 2016. PMID: 27438179
Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.
Secemsky EA, Kirtane A, Bangalore S, Jovin IS, Patel D, Ferro EG, Wimmer NJ, Roe M, Dai D, Mauri L, Yeh RW. Secemsky EA, et al. Among authors: mauri l. Circ Cardiovasc Qual Outcomes. 2017 Sep;10(9):e003741. doi: 10.1161/CIRCOUTCOMES.117.003741. Circ Cardiovasc Qual Outcomes. 2017. PMID: 28855222
In-hospital and 1-year outcomes among unselected percutaneous coronary intervention patients treated with either sirolimus- or paclitaxel-eluting stents: results from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry.
Novack V, Cutlip D, Kleiman N, Pencina M, Mauri L, Yen CH, Berger P, Goldberg S, Kellett M, Waksman R, Hong M, Raizner AE, Cohen DJ. Novack V, et al. Among authors: mauri l. JACC Cardiovasc Interv. 2009 Aug;2(8):767-75. doi: 10.1016/j.jcin.2009.05.016. JACC Cardiovasc Interv. 2009. PMID: 19695546 Free article.
Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry.
Bangalore S, Cohen DJ, Kleiman NS, Regev-Beinart T, Rao SV, Pencina MJ, Mauri L; EVENT Registry Investigators, Boston, MA. Bangalore S, et al. Among authors: mauri l. Circ Cardiovasc Interv. 2011 Oct 1;4(5):463-73. doi: 10.1161/CIRCINTERVENTIONS.111.961912. Epub 2011 Oct 4. Circ Cardiovasc Interv. 2011. PMID: 21972401 Clinical Trial.
Long-term clinical and economic analysis of the Endeavor drug-eluting stent versus the Driver bare-metal stent: 4-year results from the ENDEAVOR II trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions).
Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJ. Eisenstein EL, et al. Among authors: mauri l. JACC Cardiovasc Interv. 2009 Dec;2(12):1178-87. doi: 10.1016/j.jcin.2009.10.011. JACC Cardiovasc Interv. 2009. PMID: 20129543 Free article. Clinical Trial.
445 results